A total of 361 patients with metastatic clear cell renal cell carcinoma were randomly assigned equally to arm A ( bevacizumab monotherapy 10 mg/kg intravenously [ IV ] every 2 weeks ) , B ( bevacizumab 10 mg/kg IV every 2 weeks and temsirolimus 25 mg IV every week ) , C ( bevacizumab 5 mg/kg IV every 2 weeks and sorafenib 200 mg orally twice daily on days 1 to 5 , 8 to 12 , 15 to 19 , and 22 to 26 ) , or D ( sorafenib 200 mg twice daily and temsirolimus 25 mg IV weekly ) .